Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Receivables - Net: 2022-2024

Historic Receivables - Net for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Dec 2024 value amounting to $73.1 million.

  • Arcutis Biotherapeutics' Receivables - Net rose 91.48% to $115.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.1 million, marking a year-over-year increase of 91.48%. This contributed to the annual value of $73.1 million for FY2024, which is 183.12% up from last year.
  • According to the latest figures from FY2024, Arcutis Biotherapeutics' Receivables - Net is $73.1 million, which was up 183.12% from $25.8 million recorded in FY2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Receivables - Net peaked at $73.1 million during FY2024, and registered a low of $8.5 million during FY2022.
  • Its 3-year average for Receivables - Net is $35.8 million, with a median of $25.8 million in 2023.
  • Data for Arcutis Biotherapeutics' Receivables - Net shows a peak YoY skyrocketed of 205.12% (in 2023) over the last 5 years.
  • Over the past 3 years, Arcutis Biotherapeutics' Receivables - Net (Yearly) stood at $8.5 million in 2022, then surged by 205.12% to $25.8 million in 2023, then skyrocketed by 183.12% to $73.1 million in 2024.